Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08)-MedSci.cn

Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08)

Jhaveri, K; Hamilton, E; Loi, S; Schmid, P; Darilay, A; Gao, C; Patel, G; Wrona, M; Andre, F

CANCER RESEARCH, 2021; 81 (4):

科室
- - 订阅+
  - 更多科室
工具
服务